Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28172289 | 0.91 | MAPT (0.63) | MAPTRETKDRCYP11B1CYP11B2 | |
| SCHEMBL5096941 | 0.86 | SMN1; SMN2 (0.50) | MAPTCYP11B1CYP11B2CYP17A1KDM4E | |
| SCHEMBL14311768 | 0.85 | CYP11B1 (0.57) | MAPTRETKDRCYP11B1CYP11B2 | |
| SCHEMBL5096712 | 0.84 | CYP11B1 (0.59) | CYP11B1CYP11B2COMTGSK3B | |
| SCHEMBL5103794 | 0.84 | HCAR2 (0.54) | CYP11B1CYP11B2NTRK1CYP17A1CYP3A4 | |
| SCHEMBL5100649 | 0.84 | MAPT (0.50) | MAPTRETKDRCYP11B1CYP11B2 | |
| SCHEMBL5110899 | 0.81 | F2 (0.42) | MAPTRETKDRCYP11B1CYP11B2 | |
| SCHEMBL5100746 | 0.81 | CYP11B1 (0.47) | MAPTCYP11B1CYP11B2MAPK14COMT | |
| SCHEMBL5104024 | 0.81 | HRH3 (0.48) | CYP11B1CYP11B2MAPK14COMTGSK3B | |
| SCHEMBL5096786 | 0.81 | COMT (0.58) | MAPTCYP11B1CYP11B2CYP17A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919488-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919488-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919488-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| CN-101511812-A | Pyrazole derivatives as cytochrome P450 inhibitors | PFIZER PROD INC (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046774-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | Pfizer Products Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| WO-2008004096-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004096-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004100-A2 | THERAPEUTIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004100-A2 | THERAPEUTIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, PCSK9, CFTR | MAPT 404/4885RET 4112/4885KDR 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.